Hallervorden-Spatz syndrome
- PMID: 11551740
- DOI: 10.1016/s0887-8994(01)00253-3
Hallervorden-Spatz syndrome
Abstract
The historic and current status of Hallervorden-Spatz syndrome diagnosis, classification, and therapies are discussed. A number of symptomatic therapies are available and should be used optimally for each patient. Although one gene locus has been identified, many patients do not manifest linkage to the NBIA1 locus (neurodegeneration with brain iron accumulation). Further investigation is necessary. The lack of understanding of the basic mechanisms that underlie the syndrome have hindered the development of more meaningful classification and definitive therapies. The recent report of a defect in a novel pantothenate kinase gene (PANK2) in Hallervorden-Spatz syndrome will undoubtedly lead the way to future advances in the diagnosis and management of the syndrome. The clarification of the role of oxidative distress in the pathophysiology of the syndrome will fill a large void in the understanding of the condition.
Similar articles
-
Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome.N Engl J Med. 2003 Jan 2;348(1):33-40. doi: 10.1056/NEJMoa020817. N Engl J Med. 2003. PMID: 12510040
-
Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome.Pediatr Neurol. 2001 Aug;25(2):166-9. doi: 10.1016/s0887-8994(01)00296-x. Pediatr Neurol. 2001. PMID: 11551748
-
Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration.Mov Disord. 2004 Jan;19(1):36-42. doi: 10.1002/mds.10650. Mov Disord. 2004. PMID: 14743358
-
The nosology of Hallervorden-spatz disease.J Neurol Sci. 1995 Dec;134 Suppl:84-91. doi: 10.1016/0022-510x(95)00212-k. J Neurol Sci. 1995. PMID: 8847549 Review.
-
Iron in the Hallervorden-Spatz syndrome.Pediatr Neurol. 2001 Aug;25(2):148-55. doi: 10.1016/s0887-8994(01)00269-7. Pediatr Neurol. 2001. PMID: 11551745 Review.
Cited by
-
A novel 3-bp deletion in the PANK2 gene of Dutch patients with pantothenate kinase-associated neurodegeneration: evidence for a founder effect.Neurogenetics. 2005 Dec;6(4):201-7. doi: 10.1007/s10048-005-0018-9. Epub 2005 Oct 21. Neurogenetics. 2005. PMID: 16240131 Free PMC article.
-
Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation.Brain. 2010 Mar;133(Pt 3):701-12. doi: 10.1093/brain/awq022. Epub 2010 Mar 5. Brain. 2010. PMID: 20207700 Free PMC article.
-
Phenotypes and genotypes of patients with pantothenate kinase-associated neurodegeneration in Asian and Caucasian populations: 2 cases and literature review.ScientificWorldJournal. 2013 Nov 19;2013:860539. doi: 10.1155/2013/860539. eCollection 2013. ScientificWorldJournal. 2013. PMID: 24348190 Free PMC article. Review.
-
Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes.Int Rev Neurobiol. 2013;110:49-71. doi: 10.1016/B978-0-12-410502-7.00003-X. Int Rev Neurobiol. 2013. PMID: 24209433 Free PMC article. Review.
-
Hallervorden-Spatz syndrome: a rare cause of extrapyramidal manifestations.Ann Neurosci. 2011 Jul;18(3):133-5. doi: 10.5214/ans.0972.7531.11183012. Ann Neurosci. 2011. PMID: 25205940 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources